Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.06 DKK -1.12%
Market Cap: 524.8m DKK

Bioporto A/S
Investor Relations

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Show more
Loading
BIOPOR
OMX Copenhagen 25
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2023
Call Date
Nov 1, 2023
Q3 2023 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Other Earnings Calls

Management

Mr. Peter Moerch Eriksen B.B.A., BBA
Chief Executive Officer
No Bio Available
Mr. Niels Hoey Nielsen
Executive VP & CFO
No Bio Available
Dr. Lars Otto Uttenthal
Chief Scientific Officer
No Bio Available
Ms. Gry Husby Larsen
Executive VP & Chief Legal Officer
No Bio Available
Ms. Jennifer Zonderman
SVP of Global Marketing & US Commercialization
No Bio Available
Mr. Nis Kruse
Executive VP of Strategic Partnerships and GM of EMEA & APAC
No Bio Available
Mr. Jeffrey N. Haas
President & CEO of BioPorto Inc.
No Bio Available

Contacts

Address
Hellerup
Tuborg Havnevej 15, St.
Contacts
+4545290000.0
www.bioporto.com